Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Narlaprevir in Hepatic Impairment
NCT03832426Phase 1Completed
- Sponsor
- R-Pharm
- Start
- Nov 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of narlaprevir in hepatitis C (HCV) (4 arms), sponsored by R-Pharm. Primary endpoints: Area Under the Curve from time zero to last quantifiable concentration, Area Under the Curve from time zero to 24 hours and 4 more. Started Nov 2013; status: completed.
02
Drugs
narlaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03832426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03832426.